|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-7-9
|
|
pubmed:abstractText |
To evaluate the use of the pre-operative tumour-associated trypsin inhibitor (TATI) level and residual tumour size at primary surgery as a prognostic indicators for patients with Stage III epithelial ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0306-5456
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
508-11
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9637119-Adult,
pubmed-meshheading:9637119-Aged,
pubmed-meshheading:9637119-Aged, 80 and over,
pubmed-meshheading:9637119-Cohort Studies,
pubmed-meshheading:9637119-Female,
pubmed-meshheading:9637119-Humans,
pubmed-meshheading:9637119-Middle Aged,
pubmed-meshheading:9637119-Neoplasm, Residual,
pubmed-meshheading:9637119-Ovarian Neoplasms,
pubmed-meshheading:9637119-Preoperative Care,
pubmed-meshheading:9637119-Radioimmunoassay,
pubmed-meshheading:9637119-Retrospective Studies,
pubmed-meshheading:9637119-Risk Assessment,
pubmed-meshheading:9637119-Survival Analysis,
pubmed-meshheading:9637119-Survival Rate,
pubmed-meshheading:9637119-Trypsin Inhibitors,
pubmed-meshheading:9637119-Tumor Markers, Biological
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynaecology, University Central Hospital, Helsinki, Finland.
|
|
pubmed:publicationType |
Journal Article
|
